Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
272 studies found for:    "Herpes Zoster" [DISEASE]
Show Display Options
Rank Status Study
1 Completed Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand
Condition: Herpes Zoster
Intervention:
2 Unknown  Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster
Condition: Herpes Zoster
Interventions: Drug: Foscarnet Sodium;   Drug: Acyclovir
3 Completed Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
Condition: Herpes Zoster
Interventions: Drug: ASP2151;   Drug: Valacyclovir hydrochloride
4 Recruiting Herpes Zoster Vaccine for Bone Marrow Transplant Donors
Condition: Herpes Zoster
Intervention: Biological: Zostavax
5 Completed Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects
Condition: Herpes Zoster
Intervention: Procedure: Blood sample
6 Not yet recruiting Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
Condition: Herpes Zoster
Intervention: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
7 Completed A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster
Condition: Herpes Zoster
Interventions: Drug: EPB-348;   Drug: Valacyclovir
8 Completed Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine 1437173A;   Biological: Placebo vaccine (saline)
9 Recruiting Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster Vaccine GSK1437173A
10 Completed Herpes Zoster Prevalence in Frailty Consultations
Condition: Herpes Zoster
Intervention: Other: Medical Questionary
11 Completed Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster Vaccine GSK 1437173A
12 Completed Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster vaccine (GSK1437173A)
13 Completed Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older
Condition: Herpes Zoster
Intervention: Biological: Herpes zoster vaccine GSK1437173A
14 Active, not recruiting Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Condition: Herpes Zoster
Interventions: Biological: Herpes zoster vaccine (GSK 1437173A);   Drug: Placebo
15 Completed Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster vaccine (GSK 1437173A)
16 Completed Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
17 Active, not recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Condition: Herpes Zoster
Intervention: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
18 Active, not recruiting Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
19 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
Condition: Herpes Zoster
Interventions: Biological: GSK 1437173A;   Drug: Placebo
20 Active, not recruiting Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster Vaccine GSK1437173A

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.